Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France.

Haemophilia : the Official Journal of the World Federation of Hemophilia
Benoît PolackChloé Godard

Abstract

The development of an anti-FVIII inhibitor is the most serious complication of haemophilia A occurring in up to 30% of severe haemophilic patients. The current management of haemophilia A with inhibitor uses bypassing agents (BPA) and represents a significant therapeutic burden together with a limited adherence to prophylactic treatment. Emicizumab is the first monoclonal antibody developed in haemophilia A approved for the prevention of bleeding episodes in patients with anti-FVIII inhibitor. The purpose of this study is to evaluate the incremental cost-effectiveness ratio (ICER) of emicizumab versus BPAs. A Markov model was developed over a five-year time horizon to estimate the comparative costs and benefits of the different therapeutic approaches in this rare disease. Model inputs were clinical, including annual bleeding rate and quality of life, and economical including mainly costs of prophylaxis, bleeds and adverse events. Emicizumab treatment is dominant, ie lest costly and more effective, in the base-case analysis saving 234 191 € for a gain of 0.88 QALY. This is confirmed by both the deterministic and probabilistic sensitivity analyses. The main limit of the study remains the absence of long-term clinical data allowin...Continue Reading

References

Jun 9, 2001·The New England Journal of Medicine·P M Mannucci, E G Tuddenham
Jun 5, 2003·Lancet·Paula H B Bolton-Maggs, K John Pasi
Jun 28, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·J Wight, S Paisley
Jun 28, 2003·Haemophilia : the Official Journal of the World Federation of Hemophilia·C KnightM L Jones
Jun 29, 2004·Journal of Thrombosis and Haemostasis : JTH·S C DarbyUNKNOWN UK Haemophilia Centre Doctors' Organisation
Sep 30, 2008·Blood·Christine L Kempton, Gilbert C White
Feb 3, 2009·Clinical Reviews in Allergy & Immunology·Zera TellierBenoît Polack
Sep 22, 2011·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Julie Chevalier, Gérard de Pouvourville
Jul 11, 2012·Haemophilia : the Official Journal of the World Federation of Hemophilia·A SrivastavaUNKNOWN Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia
Aug 8, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Ben van HoutA Simon Pickard
Sep 25, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Ellis J NeufeldDavid L Cooper
Jul 3, 2013·Blood Reviews·Massimo Franchini, Pier Mannuccio Mannucci
Jan 24, 2015·American Journal of Hematology·Christopher E WalshUNKNOWN United States Hemophilia Treatment Center Network
Feb 6, 2015·Transfusion·Benoît PolackUNKNOWN EQOFIX Study Group
Feb 18, 2015·Haemophilia : the Official Journal of the World Federation of Hemophilia·S R EarnshawC M Kessler
Mar 31, 2015·British Journal of Haematology·Rolf Ljung, Nadine Gretenkort Andersson
Jun 2, 2017·Orphanet Journal of Rare Diseases·Jamie O'HaraDaniel-Anibal Garcia Diego
Jun 22, 2017·Haemophilia : the Official Journal of the World Federation of Hemophilia·W MiesbachI Pabinger
Jul 12, 2017·The New England Journal of Medicine·Johannes OldenburgMidori Shima
Oct 17, 2017·Patient Preference and Adherence·Courtney D Thornburg, Natalie A Duncan
Jun 8, 2018·Thrombosis Research·Isabella GaragiolaFlora Peyvandi
Jun 12, 2018·European Journal of Haematology·Lucia S D'AngiolellaLorenzo G Mantovani
Oct 9, 2018·Haemophilia : the Official Journal of the World Federation of Hemophilia·Johnny MahlanguRebecca Kruse-Jarres
Nov 15, 2018·Haemophilia : the Official Journal of the World Federation of Hemophilia·Johannes OldenburgSylvia von Mackensen
Apr 25, 2019·Haemophilia : the Official Journal of the World Federation of Hemophilia·Johnny MahlanguSylvia von Mackensen
Dec 31, 2019·Thrombosis and Haemostasis·Paolo Angelo CortesiLorenzo Giovanni Mantovani

❮ Previous
Next ❯

Citations

Nov 16, 2021·Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis·Daniela NemeMauro Davoli

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Clotting Disorders

Thrombophilia includes conditions with increased tendency for excessive blood clotting. Blood clotting occurs when the body has insufficient amounts of specialized proteins that make blood clot and stop bleeding. Here is the latest research on blood clotting disorders.

Related Papers

British Journal of Haematology
Sarina Levy-Mendelovich
Haemophilia : the Official Journal of the World Federation of Hemophilia
Mira GanslmeierPatrick Möhnle
© 2021 Meta ULC. All rights reserved